BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nissen SK, Ferreira SA, Nielsen MC, Schulte C, Shrivastava K, Hennig D, Etzerodt A, Graversen JH, Berg D, Maetzler W, Panhelainen A, Møller HJ, Brockmann K, Romero-Ramos M. Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. Mov Disord 2021;36:963-76. [PMID: 33332647 DOI: 10.1002/mds.28424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Kasen A, Houck C, Burmeister AR, Sha Q, Brundin L, Brundin P. Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105654] [Reference Citation Analysis]
2 Bartl M, Xylaki M, Bähr M, Weber S, Trenkwalder C, Mollenhauer B. Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105744] [Reference Citation Analysis]
3 Tajbakhsh A, Gheibihayat SM, Taheri RA, Fasihi-Ramandi M, Bajestani AN, Taheri A. Potential diagnostic and prognostic of efferocytosis-related unwanted soluble receptors/ligands as new non-invasive biomarkers in disorders: a review. Mol Biol Rep 2022. [PMID: 35419645 DOI: 10.1007/s11033-022-07224-4] [Reference Citation Analysis]
4 Koros C, Stefanis L, Scarmeas N. Parkinsonism and dementia. J Neurol Sci 2021;:120015. [PMID: 34642023 DOI: 10.1016/j.jns.2021.120015] [Reference Citation Analysis]
5 Wang T, Shi C, Luo H, Zheng H, Fan L, Tang M, Su Y, Yang J, Mao C, Xu Y. Neuroinflammation in Parkinson's Disease: Triggers, Mechanisms, and Immunotherapies. Neuroscientist 2021;:1073858421991066. [PMID: 33576313 DOI: 10.1177/1073858421991066] [Reference Citation Analysis]
6 Savinetti I, Papagna A, Foti M. Human Monocytes Plasticity in Neurodegeneration. Biomedicines 2021;9:717. [PMID: 34201693 DOI: 10.3390/biomedicines9070717] [Reference Citation Analysis]
7 Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson's disease. Acta Neuropathol 2021;141:527-45. [PMID: 33555429 DOI: 10.1007/s00401-021-02268-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
8 Fleming SM, Davis A, Simons E. Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies. Neuropharmacology 2022;202:108870. [PMID: 34742741 DOI: 10.1016/j.neuropharm.2021.108870] [Reference Citation Analysis]
9 Thaler A, Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Shirvan JC, Cedarbaum JM, Orr-Urtreger A, Regev K, Shenhar-Tsarfaty S, Mirelman A. Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. J Parkinsons Dis 2021;11:1285-96. [PMID: 33998549 DOI: 10.3233/JPD-212624] [Reference Citation Analysis]